Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep

Vaccine

Volumn 32, Issue 20, 2014, Pages 2345-2349

  Weingartl, Hana M ^a,b   Nfon, Charles K ^a   Zhang, Shunzhen ^a   Marszal, Peter ^a   Wilson, William C ^c   Morrill, John C ^d   Bettinger, George E ^d   Peters, Clarence J ^d  

^a CANADIAN FOOD INSPECTION AGENCY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

NSm deleted MP 12; Rift Valley fever; Sheep; Vaccine

Indexed keywords

NSM DELETED MP 12 VACCINE; RECOMBINANT VACCINE; RIFT VALLEY FEVER VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SHEEP; TREATMENT OUTCOME; VACCINATION;

NSM DELETED MP-12; RIFT VALLEY FEVER; SHEEP; VACCINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; IMMUNITY, CELLULAR; INTERFERON-GAMMA; NEUTRALIZATION TESTS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; RNA, VIRAL; SHEEP; SHEEP DISEASES; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA;

EID: 84897562603     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.064     Document Type: Article

References (28)

1. Pepin M., Bouloy M., Bird B.H., Kemp A., Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Veterinary Research 2010, 41(November-December (6)):61.
2. Bird B.H., Ksiazek T.G., Nichol S.T., Maclachlan N.J. Rift Valley fever virus. Journal of the American Veterinary Medical Association 2009, 234(April (7)):883-893.
3. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. Journal of Medical Virology 2006, 78(June (6)):787-791.
4. Barnard B.J. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. Journal of the South African Veterinary Association 1979, 50(September (3)):155-157.
5. Barnard B.J., Botha M.J. An inactivated rift valley fever vaccine. Journal of the South African Veterinary Association 1977, 48(March (1)):45-48.
6. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. The American Journal of Tropical Medicine and Hygiene 1995, 53(October (4)):405-411.
7. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010, 28(June (29)):4581-4587.
8. von Teichman B., Engelbrecht A., Zulu G., Dungu B., Pardini A., Bouloy M. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 2011, 29(August (34)):5771-5777.
9. Indran S.V., Ikegami T. Novel approaches to develop Rift Valley fever vaccines. Frontiers in Cellular and Infection Microbiology 2012, 2:131.
10. Oreshkova N., van Keulen L., Kant J., Moormann R.J., Kortekaas J. A single vaccination with an improved nonspreading rift valley Fever virus vaccine provides sterile immunity in lambs. PloS One 2013, 8(10):e77461.
11. Bird B.H., Maartens L.H., Campbell S., Erasmus B.J., Erickson B.R., Dodd K.A., et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. Journal of Virology 2011, 85(December (24)):12901-12909.
12. Morrill J.C., Laughlin R.C., Lokugamage N., Wu J., Pugh R., Kanani P., et al. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine 2013, Aug.
13. Morrill J.C., Peters C.J. Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine. The Journal of Infectious Diseases 2011, 204(August (4)):617-625.
14. Morrill J.C., Peters C.J. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. The Journal of Infectious Diseases 2011, 204(July (2)):229-236.
15. Morrill J.C., Laughlin R.C., Lokugamage N., Pugh R., Sbrana E., Weise W.J., et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013, 31(January (3)):559-565.
16. Wahab K.S., el-Baz L.M., el-Tayeb E.M., Omar H., Osman M.A., Yassin W. Virus isolation and identification from cases of Rift Valley fever virus infection in Egypt. The Journal of the Egyptian Public Health Association 1978, 53(3-4):201-203.
17. Nfon C.K., Marszal P., Zhang S., Weingartl H.M. Innate immune response to Rift Valley fever virus in goats. PLoS Neglected Tropical Diseases 2012, 6(4):e1623.
18. Won S., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. Journal of Virology 2007, 81(December (24)):13335-13345.
19. Bird B.H., Bawiec D.A., Ksiazek T.G., Shoemaker T.R., Nichol S.T. Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus. Journal of Clinical Microbiology 2007, 45(November (11)):3506-3513.
20. Drolet B.S., Weingartl H.M., Jiang J., Neufeld J., Marszal P., Lindsay R., et al. Development and evaluation of one-step rRT-PCR and immunohistochemical methods for detection of Rift Valley fever virus in biosafety level 2 diagnostic laboratories. Journal of Virological Methods 2012, Dec.
21. Busquets N., Xavier F., Martin-Folgar R., Lorenzo G., Galindo-Cardiel I., del Val B.P., et al. Experimental infection of young adult European breed sheep with Rift Valley fever virus field isolates. Vector Borne and Zoonotic Diseases (Larchmont, NY) 2010, 10(October (7)):689-696.
22. Won S., Ikegami T., Peters C.J., Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. Journal of Virology 2006, 80(August (16)):8274-8278.
23. Gerrard S.R., Bird B.H., Albarino C.G., Nichol S.T. The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection. Virology 2007, 359(March (2)):459-465.
24. Bird B.H., Albarino C.G., Nichol S.T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007, 362(May (1)):10-15.
25. Crabtree M.B., Kent Crockett R.J., Bird B.H., Nichol S.T., Erickson B.R., Biggerstaff B.J., et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection. PLoS Neglected Tropical Diseases 2012, 6(5):e1639.
26. Boshra H., Lorenzo G., Rodriguez F., Brun A. A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 2011, 29(June (27)):4469-4475.
27. Xu W., Watts D.M., Costanzo M.C., Tang X., Venegas L.A., Jiao F., et al. The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PloS One 2013, 8(3):e59210.
28. Lopez-Gil E., Lorenzo G., Hevia E., Borrego B., Eiden M., Groschup M., et al. A Single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Neglected Tropical Diseases 2013, 7(July (7)):e2309.